A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

Amgen is a significant win for IPG Mediabrands after Amazon moved its massive media business from Initiative to WPP and ...

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...